A novel small molecule inhibitor reduced both endogenous and drug-induced resistance to chemotherapy in a mouse model of melanoma. The NF-κB pathway is often active in human cancers and promotes resistance to cytotoxic chemotherapy drugs. Some cytostatic drugs, such as doxorubicin, induce NF-κB pathway activity.